| # | 명칭 | 등록번호 | 비고 |
|---|---|---|---|
| 37 | 고순도 인간 유도만능줄기세포 유래 심근세포와 다중 바이오마커 인공지능 모델을 이용한 약물 유발 부정맥 위험 예측 플랫폼 및 이의 용도. | 10-2026-0133973 PCT/KR2026/009841 | Evaluation of Cardiac safety pharmacology test |
| 36 | 인간 줄기세포 유래 심근세포의 임피던스 변화를 이용한 약물의 심장 안전성 평가 방법 | 10-2026-0039271 PCT/KR2026/008245 | Evaluation of Cardiac safety pharmacology test |
| 35 | 인간 줄기세포 유래 간세포의 임피던스 변화를 이용한 약물의 간 안전성 평가 방법 | 10-2026-0039270 | Evaluation of Cardiac safety pharmacology test |
| 34 | 인간 전분화능 줄기세포 유래 심근세포를 이용한 약물의 나트륨 이온 채널 영향 기반 심장 안전성 평가 방법 | 10-2025-0114009/KR | Evaluation of Cardiac safety pharmacology test |
| 33 | 마이크로 패턴화 단백질 코팅을 이용한 인간 전분화능 줄기세포 유래 심근세포의 성숙화 배양 방법 | 10-2025-0114008/KR | hiPSC derived cardiomycyte maturation |
| 32 | METHODS FOR MANUFACTURING IN VITRO DISEASE SIMULATION MODEL IN WHICH ACUTE MYOCARDIAL INFARCTION AND HERART FAILURE ARE INDUCED BY ISCHEMIA-REPERFUSION INJURY USING HEART ORGANOID DERIVED FROM HUMAN PLURIPOTENT STEM CELL AND IN VITRO DISEASE SIMULATION MODEL MANUFACTURED THEREBY | 10-2023-0164201/KR PCT/KR2024/018773 | Stem Cell organoid |
| 31 | METHODS FOR MANUFACTURING IN VITRO DISEASE SIMULATION MODEL IN WHICH ACUTE MYOCARDIAL INFARCTION AND HERART FAILURE ARE INDUCED BY ISCHEMIA-REPERFUSION INJURY USING HEART ORGANOID DERIVED FROM HUMAN PLURIPOTENT STEM CELL AND IN VITRO DISEASE SIMULATION MODEL MANUFACTURED THEREBY | 10-2023-0164201/KR PCT/KR2024/018773 | Stem Cell organoid |
| 30 | DRY POWDER INHALATION FORMULATION FOR IDIOPATHIC PULMONARY FIBROSIS TREATMENT OR PREVENTION AND MANUFACTURING METHOD THEREOF | 10-2023-0154956/KR PCT/KR2024/017628 | Use of NPT-0025 for IPF disease |
| 29 | RECOMBINANT PROTEIN FOR PERIODONTAL AND PERI-IMPLANT DISEASES TREATMENT OR PREVENTION AND COMPOSITION FOR PERIODONTAL AND PERI-IMPLANT DISEASES TREATMENT OR PREVENTION CONTAINING THEREOF | 10-2899196/KR PCT/KR2024/000905 | Peri-implant disease treatment |
| 28 | METHOD FOR EVALUATING THE FUNCTIONALITY OF 3D HEART ORGANOID DERIVED FROM HUMAN PLURIPOTENT STEM CELL | 10-2788090/KR PCT/KR2022/021634 | Stem Cell organoid |
| 27 | RECOMBINANT PROTEIN FOR ULCERATIVE COLITIS TREATMENT OR PREVENTION AND COMPOSITION FOR ULCERATIVE COLITIS TREATMENT OR PREVENTION CONTAINING THEREOF | 10-2758046/KR 7716149/JP PCT/KR2022/015344 18/682,466/US 22890195.5/EU 10000520905839/CN | Use of NP-011 for UC disease |
| 26 | POLYPEPTIDE FOR IDIOPATHIC PULMONARY FIBROSIS TREATMENT OR PREVENTION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 10-2801198/KR 12679867 B2/US 7527692/JP PCT/KR2022/008103 22833432.2/EU 202280006088.0/CN | Use of NP-011 for IPF disease |
| 25 | METHODS FOR EVALUATING CARDIAC SAFETY OF DRUG USING CARDIOMYOCYTES DERIVED FROM HUMAN STEM CELL | 10-2629870/KR 12571791 B2/US PCT/KR2022/0004331 22807608.9/EU 2023-506067/JP 202280006104.6/CN | Evaluation of Cardiac safety pharmacology test |
| 24 | METHODS FOR PREPARING HEART ORGANOID DERIVED FROM HUMAN PLURIPOTENT STEM CELL AND HEART ORGANOID DERIVED FROM HUMAN PLURIPOTENT STEM CELL PREPARED BY THEREOF | 10-2678908/KR 7606254/JP PCT/KR2022/0004329 18015970/US 22807607.1/EU 202280006108.4/CN | Stem Cell organoid |
| 23 | Method for preparing wilson's disease model based on liver organoid and use thereof | 10-2610435/KR | Stem Cell organoid |
CONTACT